A hormone drug licensed for diabetes also helps obese people lose weight when used in combination with a low-fat diet and physical exercise, according to a trial published online on Friday by The Lancet.
Liraglutide, marketed as Victoza, outperformed the established anti-obesity drug orlistat, commercialised as Alli or Xenical, among 564 European volunteers, it suggests.
Quiz on Obesity
"We are indeed much more than what we eat, but what we eat can nevertheless help us to be much more than what we are". - Adelle Davis There are thousands out there battling 'the bulge'. With childhood obesity on the rise even children are not spared. If your weight issues are threatening to weigh you down learn more about obesity by taking part in this quiz.
Advertisement
The 135 men and 429 women volunteers were divided into three groups.
One received daily liraglutide at four different dosages; the second received orlistat; and the third were given a harmless lookalike called a placebo.
![Low Cholesterol Diet - PUFA & MUFA]( "Low Cholesterol Diet - PUFA & MUFA")
In the fortnight before the trial, all the volunteers began a regime that combined daily exercise with a cut in calorie intake by 500 calories.
By comparison, 500 calories is roughly a quarter of the recommended daily energy intake for women, and about a fifth of the recommended intake for men.
Five months later, the liraglutide patients had each lost between 4.8 and 7.2 kilos (10.5 and 15.8 pounds) on average depending on the dosage; the orlistat volunteers had lost 4.1 kilos (9.0 pounds); and the placebo group 2.8 kilos (6.1 pounds).
Seventy-six percent of the high-dosage liraglutide takers lost more than five percent of their weight, compared with 44 percent in the orlistat group and 30 percent in the placebo group.
There was also a big reduction in "prediabetes" conditions among the liraglutide group.
Liraglutide was "well-tolerated," according to the study.
"Nausea and vomiting occurred more often in individuals on liraglutide than in those on placebo, but adverse events were mainly transient and rarely led to discontinuation of treatment."
Liraglutide, which is administered into the skin through an injector, was initially developed as a treatment to control blood glucose levels for patients with Type 2 diabetes.
But one of its impacts is to brake the emptying of the contents of the stomach into the intestine, thus prolonging a feeling of satiety.
The study was led by Arne Astrup, a professor of nutrition at the University of Copenhagen. He is also an advisor to liraglutide's manufacturers, the Danish company Novo Nordisk A/S. The study data was vetted by The Lancet, a peer-reviewed journal.
The authors say the results offer "a new mode of action" for treating obesity, for which only a few effective and safe drugs are available.
Obesity has reached epidemic-level proportions in many rich economies as well as in fast-growing emerging countries.
Over the past 20 years, the rate of obesity has tripled and is more than 30 percent in some European countries, according to an estimate published last year.
Volunteers in the study had a body mass index (BMI) of between 30 and 40. A BMI, one's weight in kilos divided by one's height in metres squared, that is above 30 is generally categorised as obese.
Source: AFP
SRM
Advertisement
In the fortnight before the trial, all the volunteers began a regime that combined daily exercise with a cut in calorie intake by 500 calories.
By comparison, 500 calories is roughly a quarter of the recommended daily energy intake for women, and about a fifth of the recommended intake for men.
Five months later, the liraglutide patients had each lost between 4.8 and 7.2 kilos (10.5 and 15.8 pounds) on average depending on the dosage; the orlistat volunteers had lost 4.1 kilos (9.0 pounds); and the placebo group 2.8 kilos (6.1 pounds).
Seventy-six percent of the high-dosage liraglutide takers lost more than five percent of their weight, compared with 44 percent in the orlistat group and 30 percent in the placebo group.
There was also a big reduction in "prediabetes" conditions among the liraglutide group.
Liraglutide was "well-tolerated," according to the study.
"Nausea and vomiting occurred more often in individuals on liraglutide than in those on placebo, but adverse events were mainly transient and rarely led to discontinuation of treatment."
Liraglutide, which is administered into the skin through an injector, was initially developed as a treatment to control blood glucose levels for patients with Type 2 diabetes.
But one of its impacts is to brake the emptying of the contents of the stomach into the intestine, thus prolonging a feeling of satiety.
The study was led by Arne Astrup, a professor of nutrition at the University of Copenhagen. He is also an advisor to liraglutide's manufacturers, the Danish company Novo Nordisk A/S. The study data was vetted by The Lancet, a peer-reviewed journal.
The authors say the results offer "a new mode of action" for treating obesity, for which only a few effective and safe drugs are available.
Obesity has reached epidemic-level proportions in many rich economies as well as in fast-growing emerging countries.
Over the past 20 years, the rate of obesity has tripled and is more than 30 percent in some European countries, according to an estimate published last year.
Volunteers in the study had a body mass index (BMI) of between 30 and 40. A BMI, one's weight in kilos divided by one's height in metres squared, that is above 30 is generally categorised as obese.
Source: AFP
SRM
Ideal Body Weight
Calculate the ideal body weight for adults easily with Medindia's Ideal Body Weight Calculator.
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
A commonly prescribed rheumatoid arthritis drug can suppress the progression of Type 1 diabetes, according to results of the world-first human trial.
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.